COL14127-showcase
An estimated 48.5 million couples suffer from infertility worldwide (1), driving up usage of assisted reproductive technologies around the globe. As a result, preimplantation genetic testing (PGT), has become commonplace in vitro fertilization (IVF) research, to evaluate the status of an embryo.

Commonly used PGT testing solutions:

  • Preimplantation genetic testing-aneuploidy (PGT-A): detects aneuploidies, or chromosomal abnormalities, across all 24 chromosomes (22 autosomes and the X and Y chromosomes)
  • Preimplantation genetic testing-monogenic (PGT-M): identifies specific genetic variants in a single gene associated with known predisposition within the family

Advancements in next-generation sequencing (NGS) methods enable simple, scalable, and innovative sample-to-answer workflow solutions for PGT-A and PGT-M. NGS delivers fast results from precious samples, without the complexities that come with traditional genetic analysis tools.

Hear what your peers are saying about NGS and preimplantation genetic testing:

webinar-ivf-program

Incorporating PGT-A in the IVF program: an IVF centre perspective

Conventional fertility centers usually combine two core divisions, the clinical department, and the embryology (andrology) laboratory. Currently, more centers choose to incorporate the third division, a genetic laboratory, into their IVF treatments for providing in-house service of molecular based experiments. Among these testing services, preimplantation genetic testing for aneuploidy (PGT-A) applied in embryo selection is the most widely used. Since 2014, next generation sequencing (NGS) has become the major platform for comprehensive chromosome screening (CCS). This talk would introduce the setting of a NGS workflow in a private fertility center, and how to make the entire process more convenient, efficient, and reliable with step-by-step modifications.

Ms. Andrea Tzu-Hsuan Chuang, M.Sc.
Director of NGS Lab,
Stork Fertility Center, Taiwan
webinar-pgt-a

Utility of offering combined PGT-A and PGT-M: a laboratory perspective

Integrated sequencing technology has enabled the use of both the PGT-A and PGT-M simultaneously. Reports have documented that the embryos screened for aneuploidy as well as for single gene or monogenic disorders, using the integrated technique of PGT-A and PGT-M have successfully improved the pregnancy rates from 45% to 70%.

Dr. Alpana Razdan, Ph.D.
Vice President and Head of Lab Services,
Genestrings Diagnostic Centre Pvt Ltd., India
webinar-slide-PGT

Webinar: Combined PGT-A and PGT-M analysis from a single biopsy in an IVF practice: experience, learning and benefits

Learn the powerful benefits of running in-house PGT-A and PGT-M on the same NGS platform, with a single embryo biopsy. In-house control creates flexibility to respond to each patient scenario, thereby reducing unnecessary costs and time. And combining analyses from the same sample limits impact to the embryo, while producing comprehensive findings for greatest probability of pregnancy success and genetically healthy offspring.

Tee Sze Tian, MSc Clinical Embryology Group Chief Embryologist
TMC Fertility Centre


dr-lee

presentation-slide-large

Webinar: The benefits of PGT-A, PGT-M and expanded carrier screening in IVF research

Follow the decision-making process and adoption of expanded carrier screening (ECS) and preimplantation genetic testing (PGT-A (aneuploidy) and PGT-M (monogenic) in patient care and reproductive genetics research labs.

Two presentations, followed by combined Q&A, cover:

  • Importance of preconception testing and advantages of NGS technology
  • Research data demonstrating:
    • Carrier screening capabilities and influence on family planning
    • Impact of PGT-A on pregnancy success rates
    • Advantages of PGT-M over alternative approaches

Dr Murat Cetinkaya, PhD
Istanbul Memorial Hospital Assisted Reproductive Technologies and Reproductive Genetic Center

Prof Volkan Baltaci, MD, PhD
CEO, Mikrogen Reproductive Genetics Company